AML patient 4 (Figure 6D) was a 24-year-old male FLT3-mut AML patient who had received midostaurin treatment and was admitted for worsening symptoms with a >80% blast population expressing both CD34 and CD117 (c-kit). This evidence concerns the gene KIT and acute myeloid leukemia.